Blackberry Considers Alternative To Selling Catapults As Continuation Of Covid-19 Means More Room For Adamis Pharmaceuticals Corp.
As an alternative to the $600 million non-core intellectual asset transaction it had agreed to with Catapult IP Innovations, BlackBerry ...
